FDA Approved New Gene Therapy for Sanfilippo Syndrome
The therapy for Sanfilippo Syndrome Type A carries a high cost as families navigate access to this treatment.
Updated on Sept. 23, 2026 in Allergies
The US Food and Drug Administration has approved the gene therapy UX111 to treat Sanfilippo Syndrome Type A. The treatment is designed to stop the progression of the rare condition.
Why it matters
The approval provides a potential therapeutic path for children diagnosed with the disease, though the cost of the treatment presents significant access challenges for families. This development shifts the focus toward managing the high financial barrier associated with this specialized gene therapy.
The FDA approved UX111 for Sanfilippo Syndrome Type A, a genetic disorder. The approval follows data indicating that the therapy is capable of halting the progression of the syndrome.
The players
Food and Drug Administration
The federal agency responsible for protecting public health by regulating medical products and gene therapies.
Tate Flaherty
A five-year-old patient who was diagnosed with Sanfilippo Syndrome Type A.
The details
The gene therapy UX111 works by introducing functional copies of a gene to address the underlying enzymatic deficiency that causes Sanfilippo Syndrome Type A. By restoring this process, the treatment aims to prevent the progressive decline typically seen in patients. The pharmaceutical manufacturer has set the cost at £2.95 million per patient, which necessitates complex discussions regarding insurance coverage or private funding for families.
Timeline
September 2025: Tate Flaherty was diagnosed with Sanfilippo Syndrome Type A.
September 2026: The FDA approved the UX111 gene therapy.
September 27, 2026: A charity football match was held at Pontardawe Football Club to raise funds.
Health Landscape
The approval of UX111 follows a pattern of high-cost gene therapies being authorized for rare, progressive genetic disorders. It underscores the ongoing challenge of balancing medical innovation with accessibility and insurance coverage for ultra-rare conditions.
For families navigating a diagnosis of a rare genetic syndrome, it is important to consult with a medical geneticist regarding current treatment eligibility. Discussions about potential therapy access and financial support should be held with hospital social workers or patient advocacy groups.
The takeaway
The FDA approval of UX111 offers a new scientific approach to halting Sanfilippo Syndrome Type A. Families facing rare disease diagnoses should document their care needs and connect with specialized patient advocacy organizations to explore all possible pathways for support.
Further reading
For additional context on the regulation of rare disease treatments, visit Allergies.
Source note: This article includes information reported by WalesOnline.
